Table 2.
DMB administered after permanent coronary artery ligation fails to mitigate MI-induced adverse LV remodeling and improve cardiac function in PKO mice.
| Wild-type | PKO | ||||
|---|---|---|---|---|---|
| Vehicle n = 4 | DMB n = 4 | Vehicle n = 4 | DMB n = 4 | ||
| HR | bpm | 410 ± 58.9 | 481 ± 65.1 | 431 ± 64.9 | 492 ± 55.6 |
| EF | % | 36.8 ± 2.7 | 45.2 ± 4.5* | 30.5 ± 7.8 | 32.4 ± 7.2 |
| FS | % | 17.6 ± 1.4 | 22.5 ± 2.5* | 14.5 ± 3.7 | 15.5 ± 3.6 |
| LV Vol,d | uL | 99.7 ± 23.2 | 107.5 ± 34.1 | 129.7 ± 62.3 | 145.7 ± 55.0 |
| LV Vol,s | uL | 63.2 ± 15.7 | 59.7 ± 23.4 | 92.4 ± 52.8 | 101.0 ± 49.5 |
| LVID,d | mm | 4.6 ± 0.5 | 4.8 ± 0.6 | 5.1 ± 1.0 | 5.4 ± 0.9 |
| LVID,s | mm | 3.8 ± 0.4 | 3.7 ± 0.6 | 4.4 ± 1.0 | 4.6 ± 0.9 |
| LVPW,d | mm | 0.8 ± 0.1 | 0.9 ± 0.1 | 0.7 ± 0.2 | 0.8 ± 0.1 |
| LVPW,s | mm | 1.0 ± 0.1 | 1.2 ± 0.2 | 1.0 ± 0.2 | 1.0 ± 0.2 |
| Est. scar size | % | 35.5 ± 5.1 | 32.4 ± 6.9 | 38.4 ± 6.4 | 31.2 ± 2.7 |
Echocardiograms were analyzed on day 14 post-permanent coronary artery ligation. Data is presented as mean ± standard deviation. HR, Heart rate; EF, Ejection Fraction; FS, Fractional Shortening; DMB, 2-Quinoxalinamine, 6,7-dichloro-N-(1,1-dimethylethyl)-3-(methylsulfonyl)-, 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline; LV Vol,d, Left Ventricle End-Diastolic Volume; LV Vol,s, LV End- Systolic Volume; LVID,d, LV Internal Diameter, Diastole; LVID,s, LV Internal Diameter, systole; LVPW,d, LV Posterior Wall thickness, diastole; LVPW,s, LV Posterior Wall thickness, systole. Naïve EF % 60.4 ± 6.7, FS % 29.3 ± 6.3 (n = 19); PKO baseline - EF % 56.2 ± 4.5, FS % 27.8 ± 2.3 (n = 9). *p < 0.05 vs vehicle.